Edit
Prometheus Biosciences, Inc.
http://www.prometheusbiosciences.com/Last activity: 15.07.2024
Active
Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of immune-mediated diseases, starting first with IBD.
Location: United States, California, Sorrento Valley
Employees: 51-200
Total raised: $130M
Founded date: 1995
Investors 1
| Date | Name | Website |
| - | Perceptive... | perceptive... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.11.2020 | - | $130M | - |
Mentions in press and media 10
| Date | Title | Description |
| 15.07.2024 | HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer | ROCKVILLE, Md. and SEOUL, South Korea, July 15, 2024 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) announced today the appointment of Christopher W. Slavinsky as Chief Business Development and Legal Officer. HanAll Biopharma Appoints Ch... |
| 17.04.2023 | Merck’s Deal for Prometheus Expected to Generate Billions in Additional Sales | Pharma giant Merck ‘s move to acquire biotech company Prometheus Biosciences led Citi analysts to reiterate their Buy rating on the stock Monday, citing billions of dollars in additional sales. In an early Sunday morning release, Merck (tic... |
| 16.04.2023 | Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. | /EIN News/ -- PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in infl... |
| 16.04.2023 | Merck to Boost Immunology Portfolio with $10.8 Billion Acquisition of Biotech Firm | John Lopez, Tech Times 16 April 2023, 08:04 am Pharmaceutical giant Merck & Co has announced the acquisition of Prometheus Biosciences Inc for a reported $10.8 billion, marking the latest step in Merck's ongoing efforts to strengthen it... |
| 16.04.2023 | Merck покупает биотехнологическую компанию Prometheus за $10,8 млрд | Фармацевтический гигант Merck & Co. приобретает биотехнологический стартап Prometheus Bisciences. Как следует из сообщения обеих компаний, за каждую акцию покупаемой компании Merck заплатит $200. Таким образом, вся сделка оценивается в ... |
| 16.04.2023 | Фармгигант Merck купит биотех-стартап Prometheus вдвое дороже его капитализации — за $10,8 млрд | Об одной из крупнейших за последние годы сделок на фармацевтическом рынке компании объявили в официальных релизах у себя на сайтах. Они также сообщили, что сделка подлежит одобрению акционеров Prometheus: встреча с ними намечена на 17 апрел... |
| 15.12.2020 | Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study | |
| 09.11.2020 | Prometheus Biosciences Raises $130M in Funding | Prometheus Biosciences, Inc., a San Diego, CA-based biotechnology company, raised $130m in equity financing. The round was led by Eventide Asset Management and RTW Investments, LP., with participation from new investors Perceptive Advisors,... |
| 09.11.2020 | Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease | |
| - | Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal | Merck reported second-quarter revenue that topped expectations on strong sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil. But the pharmaceutical giant posted a quarterly loss due to its acquisition of the biotech comp... |